Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which biopsy route catches more aggressive prostate cancers?

NCT ID NCT07710807

Diagnosis Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial compares two ways of taking prostate tissue samples in men with suspicious MRI findings: through the rectum (transrectal) or through the skin between the scrotum and anus (transperineal). Both methods use MRI images to guide the biopsy needle. The main goal is to see if the transperineal approach is at least as good as the transrectal approach at finding clinically significant prostate cancers, while possibly causing fewer infections. The study involves 280 men aged 50 to 75 with PI-RADS 3-5 lesions on MRI.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cognitive fusion prostate biopsy (transperineal or transrectal approach)
What this could lead to
If one approach proves better at detecting aggressive prostate cancers while causing fewer infections, it could become the preferred standard for men with suspicious MRI findings.
What could go wrong
This is a single-center trial with 280 participants, so results may not apply to all hospitals or patient groups. The study compares two established techniques, so a dramatic breakthrough is unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients aged 50-75 years. * Patients with PI-RADS 3, 4, or 5 lesions detected on multiparametric prostate magnetic resonance imaging (mpMRI). * Patients with an indication for prostate biopsy. * Patients who are willing to participate and provide informed consent. Exclusion Criteria: * Previous diagnosis of prostate cancer. * Active urinary tract infection. * Coagulopathy or bleeding disorders preventing prostate biopsy. * Absence of multiparametric prostate MRI evaluation. * No indication for prostate biopsy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinically significant prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinically significant prostate cancer Cognitive fusion Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ankara Etlik City Hospital

    RECRUITING

    Ankara, Yenimahalle, 06170, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.